Z-338
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedAbout Z-338
Z-338 is a phase 2 stage product being developed by Zeria Pharmaceutical for Dyspepsia. The current trial status is completed. This product is registered under clinical trial identifier NCT00298194. Target conditions include Dyspepsia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01973790 | Phase 3 | Completed |
| NCT00458328 | Phase 2 | Completed |
| NCT00333372 | Phase 2 | Completed |
| NCT00323817 | Phase 2 | Completed |
| NCT00298194 | Phase 2 | Completed |
Competing Products
20 competing products in Dyspepsia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| YH12852 0.1 mg + YH12852 0.25 mg + YH12852 0.5 mg + Placebo | Yuhan | Phase 2 | 52 |
| YM443 + Placebo + Moxifloxacin | Astellas Pharma | Phase 1 | 33 |
| YM443 | Astellas Pharma | Phase 3 | 77 |
| Cinitapride + domperidone | Eisai | Phase 3 | 77 |
| Rabeprazole + Rabeprazole + Rabeprazole + Placebo | Eisai | Phase 2 | 52 |
| Z-338 | Zeria Pharmaceutical | Phase 3 | 76 |
| Imonogas + Espumisan | Johnson & Johnson | Phase 3 | 77 |
| esomeprazole | AstraZeneca | Approved | 85 |
| Esomeprazole Magnesium | AstraZeneca | Approved | 85 |
| Tegaserod | Novartis | Phase 3 | 77 |
| Tegaserod | Novartis | Phase 3 | 77 |
| Tegaserod | Novartis | Phase 3 | 77 |
| Tegaserod and Placebo | Novartis | Approved | 85 |
| Tegaserod | Novartis | Phase 3 | 77 |
| Tegaserod | Novartis | Phase 3 | 77 |
| Gabapentin + Placebo | Pfizer | Phase 3 | 76 |
| Z-338 | Zeria Pharmaceutical | Phase 2 | 51 |
| Z-338 | Zeria Pharmaceutical | Phase 2 | 51 |
| Z-338 + Placebo | Zeria Pharmaceutical | Phase 3 | 76 |
| Acotiamide hydrochloride hydrate + Placebo | Zeria Pharmaceutical | Phase 3 | 76 |